PAS
ADPT icon

Park Avenue Securities’s Adaptive Biotechnologies ADPT Stock Holding History

Park Avenue Securities’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,919
Closed -$201K – 1029
2021
Q2 		$201K Buy
+4,919
New +$191K ﹤0.01% 988

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Park Avenue Securities's ADPT Position: Q3 2021 in Review

Park Avenue Securities sold out of Adaptive Biotechnologies (ADPT) in Q3 2021, closing a stake of 4,919 shares — an estimated $201K sold.

Park Avenue Securities first reported a position in ADPT in Q2 2021 and held it in 1 quarter. The position peaked at $201K in Q2 2021. 219 funds tracked by Wall St. Rank hold ADPT as of Q3 2021.

  • Park Avenue Securities reported no remaining Adaptive Biotechnologies position as of Q3 2021 after selling out during the quarter.
  • Park Avenue Securities sold 4,919 Adaptive Biotechnologies shares in Q3 2021, an estimated $201K.
  • Park Avenue Securities first reported a position in Adaptive Biotechnologies in Q2 2021 and held it in 1 quarter.
  • Park Avenue Securities's Adaptive Biotechnologies position peaked at $201K in Q2 2021.
  • 219 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2021.

Based on Park Avenue Securities's 13F filing for Q3 2021, filed 21 Oct 2021.